Emiliano Barbieri

7PUBLICATIONS
43CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 31, 2026
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

|Apr 20, 2026
Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab-Based Regimens.

|Mar 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito, Enrica Antonia Martino, Monica Galli

|Feb 03, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Enrica Antonia Martino, Daniele Derudas, Elena Rossi

|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.

Enrica Antonia Martino, Salvatore Palmieri, Monica Galli

|Mar 01, 2022
PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma.

Emiliano Barbieri, Stefano Pozzi, Roberta Gelmini

Pageof 2

Frequent Collaborators

3 joint publications

Antonella Bruzzese

3 joint publications

Massimo Offidani

2 joint publications

Roberta Della Pepa

2 joint publications

Giuseppe Mele